Login to Your Account

Pharma: Other News To Note

Wednesday, October 30, 2013
• Incelldx Inc., of Menlo Park, Calif., said it entered a deal with Bristol-Myers Squibb Co., of New York, related to the development of an assay for potential application of a molecular companion diagnostic intended to identify patients likely to benefit from treatment with a BMS drug currently in development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription